Great Point Partners LLC
Great Point Partners LLC is a private investment firm founded in 2003, headquartered in Greenwich, CT, with a team of approximately 30 professionals and additional presence in London. The firm focuses exclusively on investments in the health care industry, serving companies in the United States, Canada, and Western Europe. Great Point Partners manages both private and public equity funds, having invested over $1.7 billion since inception. Its clients include family offices, endowments, foundations, and pension funds, and the firm is known for its deep sector expertise, hands-on approach, and significant co-investment from its leadership team.
Investment Strategy
Great Point Partners specializes in lower middle market growth buyout funds for private health care companies and manages a hedge fund focusing on public life sciences companies. The firm targets investments in growing, profitable health care businesses led by management teams aiming for accelerated, sustainable growth. GPP’s private equity strategy emphasizes growth equity, recapitalizations, and management buyouts, with a focus on biopharmaceutical services and supplies, alternate site care, medical device manufacturing, and information technology-enabled businesses. Its public equity strategy (BioMedical Value Fund) uses a deep value, fundamentally focused approach targeting small- and mid-cap publicly traded biotech/life sciences companies with innovative technology. Across strategies, GPP employs a proactive sourcing model and partners closely with management teams through strategic, operational, and financial support.
Latest 13F Filing Activity
Great Point Partners LLC filed their most recent 13F report on Jun 30, 2025 disclosing 24 equity positions with a total 13F market value of $154M. The fund increased holdings in Ionis Pharmaceuticals Inc., Rezolute Inc., Legend Biotech Corp. among other positions. Great Point Partners LLC reduced exposure to Viridian Therapeutics Inc., Merus N V, Cytokinetics Inc. among others.
Top Holdings
Equity Positions (24)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
I IONS | IONIS PHARMACEUTICALS INC | 12.84% | $19.8M | 500,000 | $40.30 | $39.51 | +$12.2M |
R RZLT | REZOLUTE INC | 8.80% | $13.5M | 3,033,462 | $4.44 | $4.46 | +$11.1M |
A AMLX | AMYLYX PHARMACEUTICALS INC | 8.34% | $12.8M | 2,000,000 | $3.81 | $6.41 | +$6.4M |
L LEGN | LEGEND BIOTECH CORP | 8.08% | $12.4M | 350,000 | $34.87 | $35.49 | +$7.7M |
A ABVX | ABIVAX SA | 6.42% | $9.9M | 1,291,617 | $11.93 | $7.65 | -$357.3K |
Industry Allocation
Investment Team (17)
| Name | Role | Location | |
|---|---|---|---|
 | Principal | Greenwich, CT , United States | |
 | Senior Analyst | New York, NY , United States | |
 | Principal | Greenwich, CT , United States | |
 | Co-Portfolio Manager | New York, NY , United States | |
 | Private Equity Associate | New York, NY , United States | |
N Noah Rhodes | Senior Associate | Greenwich, CT , United States | |
T Tavi Yehudai | Senior Associate | New York, NY , United States | |
 | Principal | New York, NY , United States | |
 | Private Equity Analyst | United States | |
D David Szeto | Senior Analyst | New York, NY , United States |